PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

er the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

OCT 17 2008

THE PROPERTY OF THE PERSON OF

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY **APPLICANT**

(Use as many sheets as necessary)

Sheet 1

Complete if Known				
Filing Date	February 14, 2006			
First Named Inventor	Lawrence J. Saubermann et al.			
Art Unit	1644			
Examiner Name	David A. Saunders			
Attorney Docket Number	BU-101XX			

NON PATENT LITERATURE DOCUMENTS			
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
	REDUCED TUMOR NECROSIS FACTOR & PRODUCTION IN LIPOPOLYSACCHARIDE-TREATED WHOLE BLOOD FROM PATIENTS IN THE INTENSIVE CARE UNIT, Feb. 1994, Vol. 129, pgs. 187-192, Archives of Surgery, Montreal, Quebec		
	MONOCYTE DEACTIVATION IN SEPTIC PATIENTS: RESTORATION BY IFN-γ TREATMENT, June 1997, Vol. 3, No. 6, pgs. 678-681, Nature Publishing Group		
		Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. REDUCED TUMOR NECROSIS FACTOR & PRODUCTION IN LIPOPOLYSACCHARIDE-TREATED WHOLE BLOOD FROM PATIENTS IN THE INTENSIVE CARE UNIT, Feb. 1994, Vol. 129, pgs. 187-192, Archives of Surgery, Montreal, Quebec MONOCYTE DEACTIVATION IN SEPTIC PATIENTS: RESTORATION BY IFN-γ TREATMENT, June 1997, Vol. 3, No. 6, pgs. 678-681, Nature Publishing	

Examiner	Date	
Signature	Considered	

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: